ArticleNature cancer2022
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.Nature medicine · 2026Trial
- Machine learning-predicted chromatin organization landscape across pediatric tumors.Scientific reports · 2026Article
- Long-Read Transcriptome Sequencing and Functional Validation Reveals Novel and Oncogenic Gene Fusions in Fusion Panel-Negative Gliomas.bioRxiv : the preprint server for biology · 2026Article
- Liquiritin restores metabolic homeostasis in NAFLD by modulating AKT1/FOXO1 signaling.Frontiers in pharmacology · 2026Article
- Multiomic profiling of glioblastoma metabolic lesions reveals complex intratumoral genomic evolution and dipeptidase-1-driven vascular proliferation.Neuro-oncology · 2025Article
- Article
- Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma.Molecular cell · 2025Article
- A sequence context-based approach for classifying tumor structural variants without paired normal samples.Cell reports methods · 2025Article
- Epigenetic modifications and their roles in pediatric brain tumor formation: emerging insights from chromatin dysregulation.Frontiers in oncology · 2025Review
- (B)On(e)-cohistones and the epigenetic alterations at the root of bone cancer.Cell death and differentiation · 2025Review
- Article
- 3D genomic analysis reveals novel enhancer-hijacking caused by complex structural alterations that drive oncogene overexpression.Nature communications · 2024Article
- Comparison of germline and somatic structural variants in cancers reveal systematic differences in variant generating and selection processes.bioRxiv : the preprint server for biology · 2024Article
- Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors.Nucleic acids research · 2024Article
- SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.Nature communications · 2023Article
- Article
- Somatic structural variation signatures in pediatric brain tumors.Cell reports · 2023Article
- The 3D chromatin landscape of rhabdomyosarcoma.NAR cancer · 2023Article
- Somatic structural variation signatures in pediatric brain tumors.medRxiv : the preprint server for health sciences · 2023Article
- FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.Cancer research · 2022Article
Corrections and comments
- Commented on by
Authors and funding
40 authors at 10 institutions in 5 countries.
Frank P B DuboisDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7654-6208
Ofer ShapiraDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Noah F GreenwaldDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7836-4379
Travis ZackDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jeremiah WalaDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jessica W TsaiBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0540-4330
Alexander CraneDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Audrey BaguetteQuantitative Life Sciences, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-8011-2341
Djihad HadjadjDepartment of Human Genetics, McGill University, Montreal, QC, Canada.
Ashot S HarutyunyanDepartment of Human Genetics, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-9050-9315
Kiran H KumarDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Mirjam Blattner-JohnsonHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Jayne VogelzangDepartment of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Cecilia SousaDepartment of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Kyung Shin KangDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Claire SinaiDepartment of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Dayle K WangBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2185-1782
Prasidda KhadkaDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Kathleen LewisBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Lan NguyenBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Hayley MalkinDepartment of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Patricia HoDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4622-8188
Ryan O'RourkeDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Shu ZhangDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Rose GoldDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Davy DengDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jonathan SerranoNew York University Medical Center, New York, NY, USA.
Matija SnuderlNew York University Medical Center, New York, NY, USA.
Chris JonesDivision of Cancer Therapeutics and Department of Molecular Pathology, Institute of Cancer Research 15 Cotswold Road, Sutton, London, UK.
Karen D WrightDepartment of Pediatrics, Harvard Medical School, Boston, MA, USA.
Susan N ChiDepartment of Pediatrics, Harvard Medical School, Boston, MA, USA.
Jacques GrillDepartment of Pediatric and Adolescent Oncology and INSERM Unit 981, Gustave Roussy Institute and University of Paris Saclay, Villejuif, France.
Claudia L KleinmanDepartment of Human Genetics, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-5158-7126
Liliana C GoumnerovaDepartment of Neurosurgery, Boston Children's Hospital; Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2662-719X
Nada JabadoDepartment of Human Genetics, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-2485-3692
David T W JonesHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2036-5141
Mark W KieranBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Keith L LigonBroad Institute of MIT and Harvard, Cambridge, MA, USA. keith_ligon@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-7733-600X
Rameen BeroukhimDepartment of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. rameen_beroukhim@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-6303-3609
Pratiti BandopadhayayBroad Institute of MIT and Harvard, Cambridge, MA, USA. pratiti_bandopadhayay@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-4175-4760
Broad Institute · USHarvard University · USMcGill University · CAColumbia University Irving Medical Center · USGerman Cancer Research Center · DEBoston Children's Hospital · USInserm · FRInstitute of Cancer Research · GBJewish General Hospital · CAMcGill University Health Centre · CA
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MGenetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9MMYB family alterations in pediatric gliomasR01CA215489 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, LIGON, KEITH LLOYD · 2017 to 2021
$2.8MCharacterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine GliomasR01CA219943 · NCI · BROAD INSTITUTE, INC. · PI BEROUKHIM, RAMEEN, LIGON, KEITH LLOYD · 2017 to 2021
$2.5MTargeting vulnerabilities of PPM1D-mutant gliomasR37CA255245 · NCI · DANA-FARBER CANCER INST · PI Pratiti Bandopadhayay · 2021 to 2026
$2.4MCancer Research UK 13982Cancer Research UK 23536NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA188228NCI NIH HHS R01 CA215489NCI NIH HHS R01 CA219943NCI NIH HHS R37 CA255245
Abstract
We analyzed the contributions of structural variants (SVs) to gliomagenesis across 179 pediatric high-grade gliomas (pHGGs). The most recurrent SVs targeted MYC isoforms and receptor tyrosine kinases (RTKs), including an SV amplifying a MYC enhancer in 12% of diffuse midline gliomas (DMG), indicating an underappreciated role for MYC in pHGG. SV signature analysis revealed that tumors with simple signatures were TP53 wild type (TP53
Indexed as
Brain NeoplasmsGliomaCell Cycle ProteinsChildHistonesHumansMutationProto-Oncogene ProteinsCell Cycle ProteinsHistonesMDM4 protein, humanProto-Oncogene Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.